January 17, 2018

OBI Pharma Announces FDA Clearance Of IND Application For A Phase 1 Study Of A Monoclonal Antibody Cancer Immunotherapy (OBI-888)

First Clinical Trial to Test the Safety and Preliminary Activity of Passive Immunotherapy based on a Monoclonal Antibody targeting Globo H, a glycolipid antigen found on multiple tumor types. Taipei, …

FDA Clearance of IND Application for A Phase 1 Study of A Monoclonal Antibody Cancer Immunotherapy (OBI-888)

Date of occurrence of the event: January 17, 2018 Company name: OBI Pharma, Inc. Relationship to the Company (please enter ”head office” or ”affiliated company”): Head office Reciprocal shareholding ratios: …